News

Startup IDRx raises $122m to focus on combination drug treatments

New biotech from Alexis Borisy will test Merck KGaA, Blueprint cancer drug combo in bid to fulfill Gleevec promise

IDRx, a new biotech startup, raises $122M to develop better cancer drug combinations

Alexis Borisy, biotech’s ‘man of many hats,’ dons another